主要目的:本研究以河北奥星集团药业有限公司生产的氨酚羟考酮片（规格：盐酸羟考酮5mg和对乙酰氨基酚325mg）为受试制剂，以远藤制药有限公司（Endo Pharmaceuticals Inc）持证帕尔医药公司（Par Pharmaceutical）生产的氨酚羟考酮片(商品名：PERCOCET®，规格：盐酸羟考酮5mg和对乙酰氨基酚325mg)为参比制剂，评价在空腹/餐后条件下口服两种制剂的生物等效性。次要目的:观察氨酚羟考酮片受试制剂和参比制剂在健康人体中的安全性。

[Translation]

Primary objective: This study used oxycodone acetaminophen tablets (specifications: 5 mg oxycodone hydrochloride and 325 mg acetaminophen) produced by Hebei Aoxing Group Pharmaceutical Co., Ltd. as the test preparation and oxycodone acetaminophen tablets (trade name: PERCOCET®, specifications: 5 mg oxycodone hydrochloride and 325 mg acetaminophen) produced by Par Pharmaceutical, a licensed company of Endo Pharmaceuticals Inc., as the reference preparation to evaluate the bioequivalence of the two preparations when taken orally under fasting/postprandial conditions. Secondary objective: To observe the safety of the test preparation and reference preparation of oxycodone acetaminophen tablets in healthy humans.

Start Date11 May 2024

Sponsor / Collaborator

Hebei Aoxing Group Pharmaceutical Co. Ltd.

CTR20240649 / CompletedNot Applicable

氨酚羟考酮片人体生物等效性试验

[Translation] Bioequivalence study of oxycodone-aminophenol tablets in human body

采用单中心、随机、开放、三周期、部分重复交叉、单剂量给药设计比较空腹和餐后给药条件下，北京华素制药股份有限公司提供的氨酚羟考酮片（规格：对乙酰氨基酚325 mg/盐酸羟考酮5 mg）与PAR PHARMACEUTICAL生产、Endo Pharmaceuticals Inc持证的氨酚羟考酮片（商品名：PERCOCET®，规格：对乙酰氨基酚325 mg/盐酸羟考酮5 mg）在中国健康人群吸收程度和吸收速度的差异，并评价北京华素制药股份有限公司提供的氨酚羟考酮片的安全性。

[Translation]

A single-center, randomized, open, three-period, partially repeated crossover, single-dose design was used to compare the differences in absorption extent and rate of oxycodone acetaminophen tablets (specifications: 325 mg acetaminophen/5 mg oxycodone hydrochloride) provided by Beijing Huasu Pharmaceutical Co., Ltd. and oxycodone acetaminophen tablets (trade name: PERCOCET®, specifications: 325 mg acetaminophen/5 mg oxycodone hydrochloride) produced by PAR PHARMACEUTICAL and certified by Endo Pharmaceuticals Inc. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of oxycodone acetaminophen tablets provided by Beijing Huasu Pharmaceutical Co., Ltd.

Start Date05 Mar 2024

Sponsor / Collaborator

Beijing Wellso Pharmaceutical Co., Ltd.

CTR20240058 / RecruitingPhase 3

在骨科术后中度到重度疼痛患者中评价氨酚羟考酮缓释片的有效性和安全性的随机、双盲双模拟、阳性药平行对照的多中心Ⅲ期临床研究

[Translation] A randomized, double-blind, double-dummy, active-drug parallel-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of hydroxycodone acetaminophen sustained-release tablets in patients with moderate to severe pain after orthopedic surgery

主要目的：在骨科术后需阿片类药物镇痛的中度到重度疼痛患者中，以氨酚羟考酮片为对照，评估氨酚羟考酮缓释片的镇痛疗效；次要目的：在骨科术后需阿片类药物镇痛的中度到重度疼痛患者中评估氨酚羟考酮缓释片的安全性。

[Translation]

Primary objective: To evaluate the analgesic efficacy of hydroxycodone acetaminophen extended-release tablets in patients with moderate to severe pain who require opioid analgesia after orthopedic surgery, using hydroxycodone acetaminophen tablets as a control; Secondary objective: To evaluate the safety of hydroxycodone acetaminophen extended-release tablets in patients with moderate to severe pain who require opioid analgesia after orthopedic surgery.

Start Date18 Feb 2024

Sponsor / Collaborator

Chengdu Easton Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with Acetaminophen/Oxycodone Hydrochloride

100 Translational Medicine associated with Acetaminophen/Oxycodone Hydrochloride

100 Patents (Medical) associated with Acetaminophen/Oxycodone Hydrochloride

Literatures (Medical) associated with Acetaminophen/Oxycodone Hydrochloride

01 Feb 2023·Health economics

Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata

Article

Author: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.

Abstract:

Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.

01 Apr 2022·Archives of gynecology and obstetricsQ4 · MEDICINE

Oral analgesia in fixed-time interval administration versus spinal morphine for post-Cesarean pain: a randomised controlled trial

Q4 · MEDICINE

Article

Author: Massalha, Manal ; Yefet, Enav ; Zafran, Noah ; Rudin, Michael ; Carmeli, Julia ; Hasanein, Jamal ; Nassar, Salih ; Nachum, Zohar

PURPOSE:

To compare the efficacy of fixed-time-interval oral analgesia and spinal-morphine for management of post-Cesarean pain.

METHODS:

In this open-label, parallel-group, randomized, controlled trial, 200 women due to undergo elective Caesarean section with spinal anaesthesia were enrolled between July 2015 and April 2016. Patients were randomly assigned to receive either spinal fentanyl followed by oral doses of tramadol, paracetamol, and diclofenac at predetermined regular intervals of 6 h for the first 48 h, and rescue treatment with percocet (oxycodone and paracetamol; oral analgesia group), or spinal morphine and rescue treatment with oral tramadol, paracetamol, and diclofenac (spinal-morphine group). The primary outcomes were pain intensity during the postoperative 48 h, measured on a 10-point numeric rating scale (NRS) and expressed as area under the curve (AUC), and the number of breakthrough events of moderate to severe pain (defined as NRS score ≥ 4).

RESULTS:

The oral analgesia group compared to the spinal-morphine group had similar mean pain intensity (AUC (120 ± 35 versus 121 ± 31, respectively; p = 0.8) but more events of moderate-to-severe breakthrough pain (4.8 ± 2 versus 3.8 ± 1.7, respectively; p = 0.0002). Higher rates and longer durations of pruritus, nausea, and vomiting were reported among patients receiving spinal morphine, as compared with oral analgesia. Satisfaction scores were high in both groups (8.2 ± 2.4 versus 8.7 ± 1.8 in the oral analgesia and spinal morphine, respectively; p = 0.23).

CONCLUSIONS:

Both oral analgesia at fixed time intervals and spinal morphine are satisfactory methods for treating post-Caesarean pain.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT02440399, date of registration: 07/05/ 2015. URL: https://clinicaltrials.gov/ct2/show/NCT02440399?term=enav+yefet&rank=7 .

01 Mar 2022·Global spine journalQ3 · MEDICINE

Variability in Opioid Prescription Following Primary Single-Level Lumbar Microdiscectomy

Q3 · MEDICINE

ArticleOA

Author: Roberto, Rolando ; Agatstein, Lauren ; Javidan, Yashar ; Le, Hai ; Barber, Joshua ; Phan, Eileen ; Klineberg, Eric

Study Design::

Retrospective case series.

Objectives::

To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.

Methods::

We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).

Results::

Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, P < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.

Conclusions::

We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.

News (Medical) associated with Acetaminophen/Oxycodone Hydrochloride

19 Feb 2024

·medcitynews.com

Telehealth Advocates: HHS Has Done Its Bit on Expanding OUD Treatment; DEA Needs to Step Up

This month, the U.S. Department of Health and Human Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) took steps to expand access to opioid use disorder treatment through its new final rule, which includes a provision that permanently allows for the initiation of treatment (methadone and buprenorphine) via telehealth. However, the final rule narrowly applies to only practitioners working in Opioid Treatment Programs (OTPs) and does not include other providers like primary care physicians and addiction medicine specialists. Telehealth advocates applaud HHS’ final rule but say further action needs to be taken by the Drug Enforcement Administration (DEA) to more broadly expand access to treatment via telehealth. While HHS and SAMHSA have jurisdiction over OTPs, the prescribing of controlled substances is under the DEA’s jurisdiction. OTPs are clinics licensed by a state’s health department and require federal accreditation to dispense medication-assisted treatment (MAT) services. The telehealth capabilities for OTPs began during the Covid-19 pandemic when it was more difficult to seek treatment in person. Under the final rule, practitioners in OTPs can start patients on methadone via an audio-visual telehealth appointment and start patients on buprenorphine via an audio-only telehealth appointment. The final rule doesn’t allow for an audio-only appointment for methadone because, compared to buprenorphine, it “holds a higher risk of sedation, especially if taken by someone who already is experiencing some drowsiness,” according to the SAMHSA. In addition to the telehealth changes, the final rule also allows patients to receive take-home doses of methadone and expands provider eligibility to allow nurse practitioners and physician assistants to order medications in OTPs. It also removed criteria that required patients to have a history of addiction for a full year before being eligible for treatment. “The easier we make it for people to access the treatments they need, the more lives we can save,” said HHS Deputy Secretary Andrea Palm in a statement. “With these announcements, we are dramatically expanding access to life-saving medications and continuing our efforts to meet people where they are in their recovery journeys.” What the final rule does not include is the virtual prescribing of a broader range of controlled substances in addition to buprenorphine, such as Adderall, Percocet and Xanax. The rule also does not apply to a broader range of providers, such as primary care providers, psychiatrists and virtual providers. The DEA released a proposed rule last year that would roll back Covid-19 flexibilities that allowed a range of practitioners to prescribe controlled substances virtually. However, after receiving a record number of comments, the agency has extended the flexibilities through December of this year. And now with HHS issuing this final rule on OTPs, some are hoping the DEA will expand who is eligible to provide care through telehealth and make these flexibilities permanent. While the final rule is “really important,” one telehealth advocate is left wanting more. “We hope that this forward-looking access to care that’s been achieved through this final rule will be something that is taken up by the DEA, working in conjunction with SAMHSA on this broader overarching policy that we still don’t have a permanent foundation for. … SAMHSA has applied lessons learned to ensure appropriate levels of access for those patients who will go to treatment centers,” said Kyle Zebley, senior vice president of public policy at the American Telemedicine Association, in an interview. He added that he hopes the DEA “exceeds” what SAMHSA has done when it comes to the virtual prescribing of controlled substances. One provider who is not affected by HHS’ rule and is awaiting direction from the DEA is Bicycle Health. The Boston-based telehealth company currently offers access to buprenorphine and treats patients across 32 states. Dr. Brian Clear, chief medical officer of the company, said “it’s about time” that the HHS final rule was passed, but noted that there are limitations. In March of 2021, there were just 1,816 OTPs in the U.S., according to Pew Charitable Trusts. That just barely scratches the surface of the need when it comes to opioid use disorder. Clear argued that HHS and SAMHSA’s rulemaking is based on evidence from primary care providers and programs like Bicycle Health that shows virtual prescribing of buprenorphine is safe and effective. Therefore, it would be “absurd” if the DEA decides providers like Bicycle Health can’t also prescribe treatment virtually. Another virtual opioid use disorder provider also cheered the final rule while echoing Clear and Zebley on its limitations. “There are significant ways in which this final rule can help expand access to OTP services, but challenges also remain for patients who want or need low-barrier access to medication-based treatment for SUD,” said Ben Maclean, general counsel at Portland, Oregon-based Boulder Care. What specifically should the DEA do to expand access? Zebley of the American Telemedicine Association said the agency should create a special registration process that allows medical professionals to register with the agency in order to virtually prescribe controlled substances. Congress mandated the DEA to create this process back in 2008, but the agency has yet to do so. Zebley said it’s “dangerous to make too many predictions” about whether the DEA will follow HHS’ footsteps. However, he noted that the virtual prescribing of controlled substances has now been allowed for four years. By the time the extension ends in December, it’ll be just shy of five years. “Why would we throw the door back up, gates back up, build that wall back up and leave a lot of vulnerable patients out in the cold? I do think it is a life or death circumstance for some,” he said. “Some Americans receiving care now will have their continuity of care severed and some Americans in the future will never have this opportunity to have that level of access to care that they need when and where they need it.”

04 Jan 2024

·medcitynews.com

Star Ratings are Great for Finding a Good Restaurant; They Can Be Deadly if You Are Shopping for a Doctor

Looking for a new doctor? That’s as easy as looking for a new restaurant. Search on Yelp, Google Reviews, US News and World Report, or a dozen other online sites and you’ll find patient satisfaction scores for hundreds of thousands of doctors, rated as diners might review a chocolate souffle. These satisfaction reviews will tell you if the doctor is pleasant, reassuring, or funny. They will tell you if the staff is polite, if there are long wait times, and if there is adequate parking. Overall, they will tell you if patients are happier when they leave the office than when they came in. But there’s one big problem: patient satisfaction scores tell you nothing about whether a doctor is good at curing people. In fact, patient satisfaction scores can lead to unnecessary healthcare costs, unnecessary injuries, and in some cases, the preventable deaths of patients. Patient satisfaction scores play a major role in helping doctors attract patients and they incentivize doctors to keep patients happy. Afraid of receiving negative ratings, some physicians are intimidated into granting patient requests for tests, medications, or procedures that are expensive, unnecessary and sometimes even dangerous. Like all medical procedures, unnecessary ones can harm patients or even lead to deaths. In fact, one massive study of patients who provided satisfaction scores found that patients who were most satisfied with their doctors had higher mortality rates than dissatisfied patients. In 2012, researchers at the University of California at Davis, using data from nearly 52,000 adults, found that the most satisfied patients also spent the most on healthcare and prescription drugs. They were 12% more likely to be admitted to the hospital and accounted for 9% more in total health care costs. Strikingly, they were also the ones more likely to die. The study researchers suggested that the most satisfied patients have a higher mortality rate because they receive more discretionary services–interventions that carry a risk of adverse effects. As an orthopedic surgeon who has treated thousands of patients, I have seen the tyranny of patient satisfaction ratings at work. Say a patient demands a powerful opioid like Percocet, a highly addictive pain killer. You, as their doctor, know they should take a less powerful, non-addictive pain killer. You also suspect that the patient is an opioid addict. The right thing to do is to say no. But you also know that if you deny this patient, he can easily post terribly derogatory reviews online. Potential new patients will see those reviews and stay away. Your kids will see it and think their dad is a bad doctor. Medical peers will see it and wonder what is going on. The easiest thing to do is the wrong thing to do: write a prescription for Percocet and send the patient on his way. Don’t take my word for it. One state medical society survey of 155 respondents found that more than half had ordered inappropriate tests and prescribed inappropriate antibiotic or opioid pain medication as a result of patient satisfaction scores. A third had unnecessarily admitted a patient into hospital and almost half of respondents believed they had provided inappropriate patient care in deference to patient satisfaction ratings. In addition to focusing doctors on patient catering over patient care, subjective reviews fail to gather objective data that indicates how much improvement (or worsening) a given doctor has been able to help prior patients with similar conditions achieve. Take for example, a 5-star review from a patient who achieves 50% improvement in their symptoms after being treated by a doctor with a great bedside manner and a beautiful office. Conversely, a patient who achieves 100% improvement from a doctor with a poor bedside manner (or timeliness, parking, staff, office lighting, etc..) is likely to give them a poor review. What we really want is a way to differentiate which doctor is most likely to give us the best result. Is knowing that information even possible? Luckily, it is. Patient Reported Outcome Measures (PROMs) can provide objective data on the effectiveness of providers, as patients report their symptoms, functional status, and quality of life using science, not subjective opinions. PROMs are standardized and validated questionnaires that gather critical data on patient improvement. They are developed through extensive research and validation processes to ensure their reliability, validity, and relevance. They are the same questionnaires used in FDA studies and clinical trials. PROMs scores should be the gold standard for how patients find their doctors, not viewing subjective online reviews of doctors’ ability to satisfy their patients. For example, Newsweek and Statista recently developed a PROMs implementation survey to determine the current state of PROMs implementation in hospitals. The results of this survey were incorporated into the 2023 editions of Newsweek’s World’s Best Specialized Hospitals and World’s Best Hospitals rankings. But PROMs are generally not available to the public and gathering PROMs data requires extra work by physicians and their staffs. Nonetheless, if PROMs data were available, they would reduce healthcare costs, eliminate some unnecessary procedures, and even prevent avoidable deaths. A major step would be for the Centers for Medicare and Medicaid Services, which administers Medicare coverage for 60 million Americans, to begin meaningfully incentivizing physicians and other providers to collect PROMs data on their practices and make that data available to the public. Once government has begun a push for PROMs, the private sector is likely to follow suit, providing an alternative source of information that truly reveals who is practicing medicine well and who is not. It is time for the healthcare industry to put an end to the tyranny of subjective patient satisfaction ratings. It is more than an issue of being fair to doctors. It is a matter of doctors first doing no harm.

07 Sep 2023

·www.prnewswire.com

Cunningham Bounds: Alabama Supreme Court Upholds $10M Wrongful Death Judgment Against Springhill Medical Center

MOBILE, Ala., Sept. 7, 2023 /PRNewswire/ -- The Alabama Supreme Court recently affirmed a $10-million judgment on a Mobile County jury's verdict for the family of Mr. Jay West, who died due to unsafe use of Dilaudid that he was given after minor thumb surgery at Springhill Medical Center. The judgment is the largest that the Alabama Supreme Court has ever affirmed for a single wrongful death. The record-setting affirmance originates from an incident in June 2014. Mr. West accidentally cut his left thumb with a table saw and went to Springhill Medical Center. A minor 20-minute surgery was completed to repair the wound. No complications were reported. After the surgery, Mr. West's surgeon ordered Percocet and intravenous (IV) Dilaudid for his pain recovery. If the medical personnel had reviewed Mr. West records and the Sentinel Event Alerts from the Joint Commission for Accreditation of Healthcare Organization (JCAHO), they would have discovered that he was at "high risk for opioid-induced respiratory depression." No safety measures were taken before Mr. West was given the IV opioids. At trial testimony proved that the hospital had not trained its nursing staff on how to prevent or respond to a patient experiencing opioid-induced respiratory depression. Mr. West was placed in a recovery room in the hospital and the first round of opiates – four milligrams of IV Dilaudid – was administered to alleviate the residual pain from the thumb surgery. About two hours later, a second four-milligram IV dose of the Dilaudid was administered without any hospital monitoring. Less than eight hours later, Mr. West was found unresponsive and not breathing. Medical intervention was unsuccessful. During the trial for Mr. West's wrongful death, Dr. Kenneth Rothfield was called as an expert witness to testify about the use of Dilaudid, which carries an FDA-mandated "Black Box Warning." Dr. Rothfield testified about the amount of IV Dilaudid Mr. West received, "Well, if you were planning on killing somebody, that would be a dose that would be expected to do the job." The Alabama Supreme Court unanimously agreed that Springhill Medical Center breached the standard of care. Attorney Brian Duncan of Cunningham Bounds, who represented the West family and was joined by Attorney Robert Mitchell and Attorney David Wirtes stated, "Mrs. West deeply values the dedication and bravery demonstrated by every juror involved in the case. She expresses her heartfelt gratitude for the Alabama Supreme Court's affirmance of the Mobile County Circuit Court's rulings. After a nine-year journey, justice has at last been served for her husband's tragic and entirely avoidable death." Cunningham Bounds remains focused on and committed to fighting for plaintiffs in cases involving serious personal injury, wrongful death, medical malpractice, products liability, and complex civil litigation. For more information on Cunningham Bounds, visit: The law firm of Cunningham Bounds has offices in Mobile, Alabama and Atlanta, Georgia and has been representing plaintiffs for over 60 years. Today the firm continues its tradition of representing victims in cases involving catastrophic personal injury, industrial accidents, defective products, truck and automobile accidents, and medical malpractice. The firm also has expertise in business litigation, complex litigation, and national and state class action litigation involving defective products and consumer fraud. For more information, contact: Lauren Hart [email protected] 251.471.6191 SOURCE Cunningham Bounds

100 Deals associated with Acetaminophen/Oxycodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N02AJ17	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	US	Mallinckrodt LLC	11 Mar 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Moderate pain	Phase 3	CN	Chengdu Easton Biopharmaceuticals Co., Ltd.	18 Feb 2024
Severe pain	Phase 3	CN	Chengdu Easton Biopharmaceuticals Co., Ltd.	18 Feb 2024
Bunion	Phase 3	US	Mallinckrodt Plc	01 Nov 2011
Pain, Postoperative	Phase 3	US	Mallinckrodt Plc	01 Nov 2011
Low Back Pain	Phase 3	US	Mallinckrodt Plc	20 Sep 2011
Osteoarthritis	Phase 3	US	Mallinckrodt Plc	20 Sep 2011
Cancer Pain	Phase 1	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Aug 2023
Chronic Pain	Phase 1	CN	Chengdu Easton Biopharmaceuticals Co., Ltd.	21 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03510910 (CTgov)	Phase 4	-	100	Acetaminophen+Percocet (Acetaminophen Along With a Reduced Quantity of Percocet)	mtpcwdgsol(jdrptvyldr) = uiwnzkghrd zjeyxubque (zsievxosdx, nabfhzrbac - rqtxppieee) View more	-	07 Jan 2021
				Percocet (Percocet Only)	mtpcwdgsol(jdrptvyldr) = foutjpvbfi zjeyxubque (zsievxosdx, cmvqmuswin - cuxopqcbhl) View more
NCT01451385 (CTgov)	Phase 3	Low Back Pain \| Osteoarthritis	376	COV795	smdohsorql(ttjbgbtaud) = cpmjyczvey webjdttscz (ytegcyvwpx, auflvvlaqk - zjgnegaayj) View more	-	17 Sep 2020
NCT02508935 (CTgov)	Phase 4	Acute Pain	23	XARTEMIS XR	lbtpbwvocx(dquubcuhrm) = jpeqavpklt huqmhbeqee (teghqkulcl, antlcyvois - onjlnkuknc) View more	-	22 Jan 2020
NCT02826551 (CTgov)	Not Applicable	Pain \| Anesthesia	23	Crutches+Percocet (No Injection)	rcqqchzwiv(yjjokqtkoz) = gpyyoepwqk fdqpxyjfih (sgonqkzrga, kknvnnarme - dhhlxpfvbk) View more	-	14 Dec 2017
				Crutches+Percocet+Marcaine (Injection)	rcqqchzwiv(yjjokqtkoz) = faeemjsunn fdqpxyjfih (sgonqkzrga, yrfbztibac - dpzgucmcyi) View more
NCT02604550 (CTgov)	Phase 4	Anterior Cruciate Ligament Injuries \| Ligament pain	115	Naprosyn 500 mg+Ropivacaine 0.5%+Percocet 7.5/325 (Femoral Nerve Block)	uyrjqeglad(xzoqitbhmx) = huepgqngdr uinwhcfpzq (ebeyyqczcm, gnykkcxgli - lvsoogidej) View more	-	31 May 2017
				Naprosyn 500 mg+Ropivacaine 0.5%+Percocet 7.5/325 (Adductor Canal Block)	uyrjqeglad(xzoqitbhmx) = jxpbrqskxw uinwhcfpzq (ebeyyqczcm, dnfddizjjx - lngkmyxwbd) View more
NCT01484652 (CTgov)	Phase 3	Bunion \| Pain, Postoperative	329	COV795 (COV795)	qjdbnxyfjv(pgluewmybs) = xrkeshonzu czzwudmwdp (qrtsiuvtkh, tbohpxsvai - nfbaqqncnt) View more	-	02 Jul 2014
				placebo (Placebo)	qjdbnxyfjv(pgluewmybs) = odgveeqjbs czzwudmwdp (qrtsiuvtkh, mwotkgxxmv - xvnuykpqaq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis